CN1306027C - 一种体外扩增γδT淋巴细胞的方法 - Google Patents
一种体外扩增γδT淋巴细胞的方法 Download PDFInfo
- Publication number
- CN1306027C CN1306027C CNB021567255A CN02156725A CN1306027C CN 1306027 C CN1306027 C CN 1306027C CN B021567255 A CNB021567255 A CN B021567255A CN 02156725 A CN02156725 A CN 02156725A CN 1306027 C CN1306027 C CN 1306027C
- Authority
- CN
- China
- Prior art keywords
- cell
- gamma delta
- cells
- tcr
- substratum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000003199 nucleic acid amplification method Methods 0.000 title claims description 29
- 230000003321 amplification Effects 0.000 title claims description 28
- 230000008569 process Effects 0.000 title description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 138
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 210000002966 serum Anatomy 0.000 claims description 18
- 210000005087 mononuclear cell Anatomy 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 102000000589 Interleukin-1 Human genes 0.000 claims description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 26
- 239000002609 medium Substances 0.000 description 25
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 108010063738 Interleukins Proteins 0.000 description 21
- 102000015696 Interleukins Human genes 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 19
- 238000011580 nude mouse model Methods 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 210000005259 peripheral blood Anatomy 0.000 description 16
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 15
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 15
- 239000011886 peripheral blood Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 238000002512 chemotherapy Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 12
- 230000001472 cytotoxic effect Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 230000000735 allogeneic effect Effects 0.000 description 8
- 102000011778 gamma-delta T-Cell Antigen Receptors Human genes 0.000 description 8
- 108010062214 gamma-delta T-Cell Antigen Receptors Proteins 0.000 description 8
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 2
- 210000002203 alpha-beta t lymphocyte Anatomy 0.000 description 2
- 210000001776 amniocyte Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000003515 double negative t cell Anatomy 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
培养时间(天) | 外周血 | TAL | TIL | |||
γδTcells(%) | αβTcells(%) | γδTcells(%) | αβTcells(%) | γδTcells(%) | αβTcells(%) | |
1014212428 | 50±1171±390±5NDND | 25±412±65±3NDND | 27±655±872±477±386±6 | 33±197±613±93±34±1 | NDND52±864±383±9 | NDND25±819±78±9 |
细胞 | Hep2 | HR8348 | CA2 | 803 |
γδTILsCD3TILsγδPBMC | 16.7±0.313.9±0.516.9±2.0 | 47.0±2.834.8±2.3未检测 | 58.6±15.941.4±5.732.4±4.8 | 51.2±12.439.3±7.846.6±8.5 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021567255A CN1306027C (zh) | 2002-12-12 | 2002-12-12 | 一种体外扩增γδT淋巴细胞的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021567255A CN1306027C (zh) | 2002-12-12 | 2002-12-12 | 一种体外扩增γδT淋巴细胞的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1506456A CN1506456A (zh) | 2004-06-23 |
CN1306027C true CN1306027C (zh) | 2007-03-21 |
Family
ID=34236365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021567255A Expired - Lifetime CN1306027C (zh) | 2002-12-12 | 2002-12-12 | 一种体外扩增γδT淋巴细胞的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1306027C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102154205A (zh) * | 2011-01-31 | 2011-08-17 | 郑骏年 | 高纯度、高细胞毒活性的γδT细胞的制备方法 |
CN102994448A (zh) * | 2012-12-13 | 2013-03-27 | 上海柯莱逊生物技术有限公司 | 一种体外扩增γδT细胞的方法 |
CN107249605A (zh) * | 2014-11-17 | 2017-10-13 | 阿迪塞特生物股份有限公司 | 工程化的γδT细胞 |
IL301527A (en) | 2016-05-12 | 2023-05-01 | Adicet Bio Inc | Methods for selective expansion of gamma delta T-cell populations and preparations thereof |
CN108070554A (zh) * | 2016-11-15 | 2018-05-25 | 首都医科大学附属北京天坛医院 | 一种用于体外扩增细胞毒性γδT淋巴细胞的药物组合及其扩增方法 |
CN107177549A (zh) * | 2017-06-29 | 2017-09-19 | 青岛麦迪赛斯医疗技术有限公司 | 一种简单高效的扩增γδT细胞的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023728A1 (en) * | 1996-11-27 | 1998-06-04 | Ludwig Institute For Cancer Research | Cellular adjuvant |
WO2000025813A1 (en) * | 1998-10-29 | 2000-05-11 | Dana-Farber Cancer Institute | CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
JP2000184880A (ja) * | 1998-10-14 | 2000-07-04 | Kanegafuchi Chem Ind Co Ltd | ガン細胞特異的傷害性t細胞の増殖・活性化誘導方法及びそれに用いるデバイス |
CN1275618A (zh) * | 2000-06-21 | 2000-12-06 | 张国庆 | 一种t-淋巴细胞培养方法 |
CN1280194A (zh) * | 2000-06-21 | 2001-01-17 | 张国庆 | 一种t-淋巴细胞培养液 |
-
2002
- 2002-12-12 CN CNB021567255A patent/CN1306027C/zh not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998023728A1 (en) * | 1996-11-27 | 1998-06-04 | Ludwig Institute For Cancer Research | Cellular adjuvant |
JP2000184880A (ja) * | 1998-10-14 | 2000-07-04 | Kanegafuchi Chem Ind Co Ltd | ガン細胞特異的傷害性t細胞の増殖・活性化誘導方法及びそれに用いるデバイス |
WO2000025813A1 (en) * | 1998-10-29 | 2000-05-11 | Dana-Farber Cancer Institute | CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
CN1275618A (zh) * | 2000-06-21 | 2000-12-06 | 张国庆 | 一种t-淋巴细胞培养方法 |
CN1280194A (zh) * | 2000-06-21 | 2001-01-17 | 张国庆 | 一种t-淋巴细胞培养液 |
Also Published As
Publication number | Publication date |
---|---|
CN1506456A (zh) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103800898B (zh) | 一种肿瘤特异性杀伤细胞制剂及其制备方法 | |
CN105087487B (zh) | 一种高效扩增cik的方法 | |
CN102174469B (zh) | 一种有效培养肿瘤浸润淋巴细胞的方法 | |
CN101302491B (zh) | 高效扩增活化淋巴细胞的方法和培养系统 | |
CN102433303A (zh) | 用于t淋巴细胞的体外培养方法 | |
CN109481666A (zh) | 一种人体血液肿瘤pdx模型的建立方法 | |
CN104789527A (zh) | 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品 | |
CN1237170C (zh) | 自然杀伤细胞的增殖方法 | |
CN1306027C (zh) | 一种体外扩增γδT淋巴细胞的方法 | |
CN102319426B (zh) | 一种去除调节性t细胞的特异性肿瘤疫苗的制备方法 | |
CN1699558A (zh) | 使用生物反应器对造血干细胞来源的细胞因子诱导的杀伤细胞的大规模培养技术 | |
CN103173411A (zh) | 一种制备树突状细胞的方法及其试剂盒 | |
CN1990044A (zh) | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 | |
CN1745104A (zh) | 特异于类浆细胞树突状细胞的抗体 | |
CN110484504B (zh) | 一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法 | |
CN106222141A (zh) | Nk细胞培养液和细胞培养方法 | |
CN102517213A (zh) | 用于t淋巴细胞的体外培养试剂盒 | |
CN105505871B (zh) | 一种有效扩增cik且提高其特异性杀瘤能力的方法 | |
CN1311071C (zh) | 一种治疗自身免疫病的方法 | |
CN101418283A (zh) | 一种简单高效地制备cik细胞的方法 | |
CN106103701A (zh) | 改造的自然杀手细胞及其组成与用途 | |
CN106047809A (zh) | 一种联合tlr7配体同时扩增人cik/nk细胞的方法 | |
CN107417809A (zh) | 硫酸软骨素用于扩增cik细胞、制备cik细胞扩增试剂和包被培养器皿的用途 | |
CN1703506A (zh) | 在均相体系中大规模培养t-淋巴细胞的方法 | |
CN102643783A (zh) | 一种用于免疫细胞治疗的活化单个核细胞的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170705 Address after: 100176, Beijing economic and Technological Development Zone, No. 14, Zhonghe street, 1, building 104-1, room 1, Beijing Patentee after: The good moral in Beijing and cell therapy technology Co.,Ltd. Address before: 100005 No. three, No. 5, Beijing, Dongdan Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070321 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Yao Qingliang Document name: Notice of termination upon expiration of patent right |